Crossmark

High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells

Crossref DOI link: https://doi.org/10.1007/s00277-021-04493-0

Published Online: 2021-03-31

Published Print: 2021-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zeng, Zhihong

Ly, Charlie

Daver, Naval

Cortes, Jorge

Kantarjian, Hagop M.

Andreeff, Michael

Konopleva, Marina https://orcid.org/0000-0002-9347-2212
Funding

Funding for this research was provided by:

National Institutes of Health/National Cancer Institute Leukemia SPORE grant Career Development Award (P50 CA100632)

National Cancer Institute (CA155056-04)

Leukemia and Lymphoma Society (6427-13)

the Paul and Mary Haas Chair in Genetics

NIH/NCI under Cancer Center Support Grant (P30 CA016672)
License Information

Text and Data Mining valid from 2021-03-31

Version of Record valid from 2021-03-31
More Information

Article History

Received: 9 February 2021

Accepted: 8 March 2021

First Online: 31 March 2021

Declarations

:

: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below